Company Overview - Longevity Health Holdings, Inc. (XAGE) focuses on advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition [1][3] - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [3] Recent Financial Activity - XAGE successfully sold 479,621 shares of common stock at an average price of $4.08 per share, generating gross proceeds of approximately $1.96 million before fees and expenses [1] - This financing extends XAGE's cash runway into Q1 FY26, assuming no growth beyond the pro forma consolidated FY24 sales and not factoring in the planned merger with 20/20 [2] Strategic Developments - The company is moving forward with a planned merger with 20/20 BioLabs, which develops innovative laboratory tests for chronic disease risk management [3][4] - The successful ATM offering reflects continued investor confidence in XAGE's vision and growth strategy, as stated by the CEO Rajiv Shukla [3]

Core Viewpoint - Longevity Health Holdings, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon meeting initial listing rules following its proposed merger with 20/20 BioLabs by September 2, 2025 [1][3]. Company Overview - Longevity Health Holdings focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][4]. - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [4]. Merger Details - The proposed merger with 20/20 BioLabs includes a strategic plan to effect a 1-for-30 reverse stock split to meet Nasdaq's listing requirements [2]. - The S-4 registration statement for the merger was filed on May 8, 2025, and the reverse stock split was executed on May 12, 2025 [2]. 20/20 BioLabs Overview - 20/20 BioLabs specializes in developing innovative laboratory tests for early detection and management of chronic disease risks, including a multi-cancer early detection blood test available in the U.S. [5]. - The company plans to introduce a new blood test for monitoring chronic inflammation, which is linked to several leading causes of death in America [5].

Core Viewpoint - Longevity Health Holdings, Inc. has announced a reverse stock split at a ratio of 1-for-30, which was approved by stockholders and is set to take effect on May 12, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 30.1 million to about 1 million shares [3]. - The effective time for the reverse stock split is set for May 12, 2025, with trading on a split-adjusted basis expected to begin on May 14, 2025 [2][3]. - No fractional shares will be issued; any fractional shares will be rounded up to the nearest whole share [4]. Group 2: Stockholder and Trading Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares, while those in brokerage accounts will have their positions automatically adjusted [4]. - Proportional adjustments will be made to the number of shares issuable upon exercise of outstanding stock options and warrants, as well as the exercise prices [5]. Group 3: Company Overview - Longevity Health Holdings, Inc. focuses on bio-aesthetics, particularly in longevity and healthy aging, with product lines including Carmell Secretome™ and Elevai Exosomes™ [7]. - The company sells its products through business-to-business, direct-to-consumer, and distributor sales channels in the United States [7].

As filed with the Securities and Exchange Commission on September 19, 2024. Registration No. 333-281987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5912 85-1399981 (I.R.S. Employer Identification No. ...

As filed with the Securities and Exchange Commission on September 16, 2024. Registration No. 333-281987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5912 85-1399981 (I.R.S. Employer Identification No. ...

As filed with the Securities and Exchange Commission on September 6, 2024. Registration No. 333-[*] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) 120 Newport Center Drive, Ste. 250 Newport Beach, CA 92660 (866) 794-4940 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Graydon Ben ...